The U.S. Department of Defense has released detailed instructions regarding a new mandatory screening policy for testosterone deficiency among active-duty and reserve service members aged 30 and above. This policy follows an announcement made in July by U.S. Secretary of Defense Pete Hegseth.

Effective immediately, the guidance outlines standardized screening and treatment procedures for both male and female service members. The Pentagon aims to enhance military readiness by identifying and addressing hormonal and energy-related issues.

Hegseth, an advocate for testosterone use, introduced the mandate last month, sparking discussions among experts about its scientific basis. The U.S. Food and Drug Administration is scheduled to convene a panel of experts in mid-September to discuss the medical utilization of testosterone.

As per the guidance, men aged 30 and older will undergo mandatory testosterone blood tests, while younger men will be tested only upon request or if warning signs are detected by healthcare providers. While routine testosterone testing is not mandated for women, screening is advised for symptoms like fatigue and irregular menstrual cycles, which could indicate hormonal imbalances such as low-energy availability and relative energy deficiency in sport.

The document also provides criteria for the off-label prescription of testosterone in women, particularly for postmenopausal individuals experiencing significantly reduced sexual desire. Some medical professionals have expressed concerns that widespread testosterone testing may lead to unnecessary or potentially harmful treatments, emphasizing the lack of substantial evidence supporting the notion that universal screening for low testosterone would enhance U.S. military combat readiness.